Phase 4 N=20 Brain Imaging of Quetiapine Response in Anxious Depression
Major Depression
Primary: 17-item Hamilton Depression Rating Scale (HDRS) — 20; 8 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,081 Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants
Hepatitis C
Primary: Percentage of Participants Who Achieved Sustained Virologic Response (SVR) 12 Weeks After the End of Treatment (SVR12) — 68.6; 68.9; 69.4; 52.5 percentage of participants
N/A N=200 Randomized Trial of Diphenhydramine Versus Continued Midazolam in "Difficult-to-sedate" Patients Undergoing Colonoscopy
Sedation · Endoscopy
Primary: Number of Patients Who Achieve Adequate Sedation to Allow Colonoscopy (Defined as MOAA/S ≤3) — 27; 65 participants — p=<0.001
N/A N=618 Using Stories to Address Disparities in Hypertension
Hypertension
Primary: Systolic BP at Follow-up — 137.9; 141.2 mmHg
Phase 4 N=240 Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis
Candidiasis, Vulvovaginal
Primary: Therapeutic Efficacy 1 — 102; 98 participants — p=0.925
N/A N=154 Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Disorder With Hyperactivity
Primary: Social Behavior-Negative Verbalizations — 73.32; 45.41; 28.41; 15.08 Number of Observed Behaviors
Phase 2 N=173 Efficacy and Safety of Intranasal Ketorolac for the Acute Treatment of Migraine
Migraine
Primary: The Number of Treated Subjects Who Became Pain-free (International Headache Society Grade of 0 = no Pain) by Observation Time Point. — 12; 7 participants
N/A N=10 Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome
Prader-Willi Syndrome
Primary: Change in Weight — -.5 kg — p=.07
N/A N=206 Safety Follow-Up to HP 802-247-09-015
Venous Leg Ulcer · Venous Stasis Ulcer
Primary: The Number of Participants With Closed Target Ulcers at Each Visit — 27; 21; 25; 23 participants
N/A N=418 Targeted Infection Control in Long-term Care
Infection
Primary: Total Number of MDRO (Multidrug Resistant Organisms) Isolated — 1299; 1732 Total Number of MDRO isolates — p=<0.05
Phase 2 N=301 A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
Asthma
Primary: Change in FEV1 — -0.40; 0.69; -0.59 percentage of change
Phase 1 N=109 Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male Subjects
Healthy
Primary: Area Under the Concentration-time Curve From Time Zero to Infinity (AUCinf) — 34783.4; 35889.9; 37370.3 µg·h/mL
N/A N=125 Evaluation and Control of WAG in PACU Within Patient and Caregiver Breathing Zone
Waste Anesthetic Gas (WAG) Emanating From Patients Post-operative Recovery
Primary: Waste Anesthetic Gas Measured by Parts Per Million Within PACU Caregiver's Breathing Zone With Caring for Patients — 60.6; 56.9 parts per million — p=0.24
Phase 2 N=45 Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
Prostatic Neoplasms
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs) — 41 Participants
N/A N=20 Pharmacokinetic Alterations During ECMO
Acute Respiratory Failure
Primary: Cumulative Fentanyl Equivalents From ECMO Initiation to Decision to Achieve Wakefulness — 330; 834 mg